Imbrium Therapeutics, a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma, has signed a strategic research and development collaboration with TetraGenetics, a biotech company developing novel therapeutics for pain indications and autoimmune diseases, it was reported yesterday.

The collaboration is aimed at using TetraGenetics' antibody discovery technology platform (TetraExpress) in the discovery and development of non-opioid biologic therapies for the treatment of chronic pain.

The companies jointly intend to bring to market long-acting, non-opioid therapeutics that can treat a variety of pain conditions.